A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

Inclusion Criteria: * Healthy participants as determined by no clinically significant deviation from normal in medical history, physical examination, vital signs, ECGs, and clinical laboratory determinations * Body Mass Index (BMI) of 18.0 to 30.0 kg/m2, inclusive. BMI = weight (kg)/\[height (m)\]2 * Body weight ≥40.0 kg Exclusion Criteria: * History of clinically significant infection within 4 weeks of dosing on Day 1 * Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population * History of clinically significant allergic reaction to any drug, biologic, food or vaccine Other protocol-defined inclusion/exclusion criteria apply